An anticoagulant too good to be true for revascularisation

The Lancet

Volumn 387, Issue 10016, 2016, Pages 314-315

  Verheugt, Freek W A ^a  

^a ONZE LIEVE VROUWE GASTHUIS   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANIVAMERSEN; ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 9A; HEPARIN; HIRULOG; PEGNIVACOGIN; APTAMER; PEPTIDE FRAGMENT;

ACUTE CORONARY SYNDROME; ANTICOAGULANT THERAPY; BLEEDING; CEREBROVASCULAR ACCIDENT; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; NOTE; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; ANTAGONISTS AND INHIBITORS; FEMALE; MALE;

ANTICOAGULANTS; APTAMERS, NUCLEOTIDE; FACTOR IXA; FEMALE; HUMANS; MALE; PEPTIDE FRAGMENTS; PERCUTANEOUS CORONARY INTERVENTION;

EID: 84959478205     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(15)00727-8     Document Type: Note

References (9)

1. PG Steg, SK James, D Atar et al. ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation Eur Heart J 33 2012 2569 2619
2. M Roffi, C Patrono, J-P Collet et al. 2015 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC) Eur Heart J 2015 10.1093/eurheartj/ehv320 published online Aug 29.
3. JW Eikelboom, SR Mehta, SS Anand, C Xie, KA Fox, S Yusuf Adverse impact of bleeding on prognosis in patients with acute coronary syndromes Circulation 114 2006 774 782
4. CK Dyke, SR Steinhubl, NS Kleiman et al. First-in-human experience of an antidote-controlled anticoagulant using RNA aptamer technology: a phase 1a pharmacodynamic evaluation of a drug-antidote pair for the controlled regulation of factor IXa activity Circulation 114 2006 2490 2497
5. MY Chan, MG Cohen, CK Dyke et al. Phase 1b randomized study of antidote-controlled modulation of factor IXa activity in patients with stable coronary artery disease Circulation 117 2008 2865 2874
6. TJ Povsic, JP Vavalle, LH Aberle et al. A phase 2, randomized, partially blinded, active-controlled study assessing the efficacy and safety of variable anticoagulation reversal using the REG1 system in patients with acute coronary syndromes: results of the RADAR trial Eur Heart J 34 2013 2481 2489
7. AM Lincoff, R Mehran, TJ Povsic on behalf of the REGULATE-PCI Investigators Effect of the REG1 anticoagulation system versus bivalirudin on outcomes after percutaneous coronary intervention (REGULATE-PCI): a randomised clinical trial Lancet 2015 published online Nov 4. http://dx.doi.org/10.1016/S0140-6736(15)00515-2
8. Y Han, J Guo, Y Zheng et al. Bivalirudin vs heparin with or without tirofiban during primary percutaneous coronary intervention in acute myocardial infarction: the BRIGHT randomized clinical trial JAMA 313 2015 1336 1346
9. A Kastrati, F-J Neumann, J Nehilli for the ISAR-REACT 3 Trial Investigators Bivalirudin versus unfractionated heparin during percutaneous coronary intervention N Engl J Med 359 2008 688 696